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Sodium tetradecyl sulphateAbstract Background: Varicose and ectatic cutaneous vessels are common chronic conditions that
might need surgical treatment. There are several treatment modalities, but all can cause complica-
tions and have signiﬁcant recurrence rates. A new effective and safe treatment with low or no recur-
rence is needed. Phenol seems to be a potential therapeutic agent.
Objective: To assess the efﬁcacy and safety of phenol as a sclerosing agent in the treatment of
varicose veins and other vascular ectatic conditions.
Methods: The dorsal ear veins of white New Zealand rabbits were injected with 0.1 ml of a scle-
rosing agent. Four experimental groups were used to test the sclerosant efﬁcacy of different concen-
trations of phenol (1%, 5%, 20% and 50%). Sodium tetradecyl sulphate (STS), a commonly used
sclerosing agent, was used as a positive control, while normal saline was used as a negative control.
The blood vessels of the treated ears were photographed before and 1 h, 2 days, 8 days and 45 days
after treatment. Biopsies from the treated areas were obtained for histologic examinations.
Results: A concentration of 1% phenol was too low to cause signiﬁcant vascular changes,
whereas a concentration of 5% phenol caused 90% lumen narrowing. Interestingly, 1% STS only
caused 25% lumen narrowing. Concentrations of 20 and 50% phenol caused 100% lumen narrow-
ing but caused haemorrhage and necrosis. Toxicity monitoring showed no apparent haematologic,
cardiac, pulmonary, hepatic or renal toxicity associated with the concentrations of phenol used in
this study.
72 K.M. AlGhamdi et al.Conclusion: A concentration of 5% phenol appears to be a potent and safe sclerosing agent for
ectatic small vessels. This provides a signiﬁcant new therapeutic option, which may eventually
advance to the clinic and have an impact on the treatment of patients suffering from varicose veins
and other vascular ectatic conditions.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Varicose veins (VV) and superﬁcial ectatic vessels are enlarged
vessels near the surface of the skin, which most commonly de-
velop in the legs and ankles (Yao, 2003). VV develops when
valves become faulty and vein walls become weakened (Yao,
2003; Brand et al., 1988). Normally, the one-way valves in
these veins keep the blood ﬂowing efﬁciently against gravity
up towards the heart (Brand et al., 1988). When these valves
do not function properly, blood pools, pressure builds up,
and the veins become weakened and enlarged. This is called ve-
nous insufﬁciency (Yao, 2003). VV is a common vascular dis-
order. It is estimated that up to 73% of females and 56% of
males have VV (Brand et al., 1988; Beebe-Dimmer et al.,
2005). VV have a deleterious effect on disease-speciﬁc and
general health-related quality of life (Beebe-Dimmer et al.,
2005).
The main approaches to treatment of VV include open sur-
gery, endovenous laser ablation and sclerotherapy (Evans
et al., 1999). Regardless of the treatment technique, VV recur-
rence continues to be a challenge for vascular and dermato-
logic surgeons (Sadick, 2005; Juhan et al., 1990). In addition,
all of these therapeutic modalities have many drawbacks. Sur-
gery has many disadvantages, such as high inpatient hospital
costs, prolonged recovery periods and signiﬁcant recurrence
rates (Bergan and Pascarella, 2005; Bergan, 2001). Endove-
nous laser ablation involves inserting a laser ﬁbre through
the skin and directly into the VV. The laser heats the lining
within the vein, damaging it and causing it to collapse, shrink
and eventually disappear (Pronk et al., 2010). This can cause
many complications, which include deep vein thrombosis,
cutaneous thermal injury, saphenous nerve injury, phlebitis
and bruising (Pronk et al., 2010; Ash and Moore, 2010). Scle-
rotherapy also causes numerous side effects and has signiﬁcant
recurrence rates (Sadick, 2005). Sodium tetradecyl sulphate
(STS), a sclerosing agent, has been used to treat VV since
1946 (Blenkinsopp, 1968). STS has some side effects, such as
residual pigmentation, thrombophlebitis, necrosis and ulcera-
tion (Blenkinsopp, 1968; Kanter, 1995). Therefore, new effec-
tive and safe therapeutic modalities for VV, with low or no
recurrence, are needed.
Phenol is used in nail matrixectomy, which is a surgical pro-
cedure used to treat ingrown toenail. In this procedure, 90%
phenol is applied to the matrix of the toenail to prevent the
re-growth of the treated part of the nail (Di Chiacchio et al.,
2010). One- to three-millilitre injections of 5% phenol in al-
mond oil are used to treat haemorrhoids, where the mechanism
of action is ﬁbrosis of the submucosa, which thereby obliter-
ates the redundant tissue (Halverson, 2007). These ﬁndings
indicate that phenol could be a promising therapeutic agent
for VV. Therefore, in this study, phenol was used as a potential
sclerosing agent for rabbit dorsal ear veins. The rabbit dorsal
ear vein has previously been used as a model for VV (Martinand Goldman, 1990). Previous studies showed that this
experimental model provided an accurate method to compare
different sclerosing solutions and concentrations (Goldman
et al., 1990). This study illustrates the sclerosing effects of
intravascular phenol injections on the dorsal rabbit ear vein,
which is compared to that of the standard sclerosing agent,
STS (positive control), and a negative control (normal saline).
The safety of phenol in this animal model was also assessed by
evaluating haematologic, cardiac, hepatic, renal and pulmon-
ary toxicities.
2. Materials and methods
A sclerosing agent was injected into the dorsal rabbit ear vein
after clamping on both sides of the vein. The visible effects and
histopathologic changes were observed, recorded and ana-
lysed. The dorsal rabbit ear vein was chosen because it is clear
and easy to inject and handle.
2.1. Laboratory animals
The study included 35 New Zealand rabbits. The rabbits were
approximately 13 weeks old and weighed on average 2.0 kg
each. The dorsal lateral parts of the rabbit left ears were
shaved of fur. All the animals were treated in a humane way
by ensuring they received environmental enrichment. This will
be achieved by providing ready access to fresh water and food,
an appropriate environment including shelter and rapid diag-
nosis and treatment. The study was approved by the ethics
committee of the King Khalid University Hospital.
2.2. Experimental groups
The study included a total of six groups of ﬁve rabbits each.
Four experimental groups were used to test different concentra-
tions of phenol (1%, 5%, 20% and 50%). Phenol was diluted in
sterile saline (10 mg/ml, 50 mg/ml, 200 mg/ml and 500 mg/ml,
respectively). The other two groups included a positive
control group, where the dorsal left ear veins of rabbits were in-
jected with STS, and a negative control group, in which the
animals were injected with sterile saline solution. The STS
concentration effective in the treatment of this vessel size is
1% (Tretbar, 1989), which was the concentration used for
our comparison.
2.3. Method of injection
The dorsal left ear veins of non-anaesthetised rabbits were in-
jected with 0.1 ml of the tested sclerosing material. Distal
occlusion of the dorsal vein of the rabbit’s left ear was achieved
using a surgical clamp for 10 min after the injection to prevent
the injected drugs from reaching the systemic circulation.
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The blood vessels of the treated ears were photographed before
the treatment. They were also photographed at 1 h and 1, 8
and 45 days after the treatment. Two rabbits from each group
were later anaesthetised with ketamine injections on those days
to take biopsies from the treated areas for histologic examina-
tions. The biopsies were taken from only two rabbits in each
group to ensure the possibility of visible assessment of the ves-
sels in the rest of the rabbits without the damage caused by the
biopsy. The biopsies were performed under aseptic conditions
with a 4 mm punch biopsy instrument. The samples were kept
in 10% formol saline until the time of histopathologic
processing.
2.5. Histologic assessment
The tissue samples obtained were processed, parafﬁn embed-
ded and sectioned according to standard methods using Tis-
sue-Tek TEC and Tissue-VIP (Sakura Finetek USA, Inc.
Torrance, CA) as embedding and tissue processor respectively.
The histology slides were subsequently stained with haematox-
ylin and eosin using Leica ST 520 automated stainer (Wetzlar,
Germany).
The presence of inﬂammation, vascular proliferation, lu-
men narrowing and ﬁbrosis was assessed and recorded. The
diameters of the blood vessels were assessed microscopically
(Nikon – eclipse 80i, Melville, NY) using the standard ruler
on the microscope stage. A score was given according to the
criteria we proposed (Table 1).
Our scoring system gave a maximum of 10 points for the
optimum sclerosing agent. Additional features were also de-
scribed, including haemorrhage, oedema, eosinophilic inﬁltra-
tion, granulomatous reaction, necrosis and ulceration.
2.6. Toxicity monitoring
To monitor toxicity, blood was collected from the marginal left
ear vein before treatment as a baseline and then on days 1 andTable 1 Our proposed scoring system used to assess the histologic
Criteria Grading
1 Inﬂammation No inﬂammation present
Inﬂammatory cells covered one
Inﬂammatory cells covered two
Inﬂammatory cells covered thr
2 Vascular proliferation Absent
Small and newly formed blood
3 Lumen narrowing No lumen narrowing present
625% lumen narrowing
26–50% lumen narrowing
51–75% lumen narrowing
76–100% lumen narrowing
4 Fibrosis Absent
Fibrosis covered one HPF
Fibrosis covered two or more
Total maximum score8 post-treatment. Blood was kept for 30 min at room temper-
ature, followed by 2 h on ice for clotting and then centrifuga-
tion at 3,000g for 10 min to separate serum, which was then
stored at 80 C until analysis. The toxicity of phenol was
monitored by conducting the following tests on randomly
selected subgroups (n= 3) of rabbits.
2.6.1. Haematologic monitoring
Complete blood count was performed on an aliquot of the
blood sample using an automated analyser (Sysmex
XE-2100, Sysmex Corporation, Kobe, Japan).
2.6.2. Cardiovascular monitoring
The elevation of serum concentrations of the cardiac isoen-
zymes creatine kinase-myocardial band (CK-MB) and cardiac
troponin T (cTnT) was monitored. Serum CK-MB was
measured using diagnostic kits from Sigma Chemical Co.
(St. Louis, MO, USA). Furthermore, serum cTnT was
measured using an ELISA kit (Enzyme-Test Cardiac T TnT;
Boehringer Mannheim, Indianapolis, IN, USA) (Mair et al.,
1992).
On day 45, the animals used in toxicity monitoring were
sacriﬁced, and the hearts from each group were dissected
out, immersed in 10% formol saline and sent for histopatho-
logic examination.
2.6.3. Assessment of liver function
As markers of hepatocyte necrosis, aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) activities in serum
were determined using commercially available diagnostic kits
(Biosystems, Barcelona, Spain).
2.6.4. Assessment of kidney function
Blood urea nitrogen (BUN) levels were measured in serum with
the colorimetric endpoint BUN diagnostic kit (Sigma, St.
Louis, MO). Serum creatinine levels were also determined with
the colorimetric endpoint creatinine diagnostic kit (Sigma, St.
Louis, MO).changes of the blood vessel injected with a sclerosing agent.
Score
0
high-power microscopic ﬁeld (HPF) 1
HPFs 2
ee or more HPFs 3
0
vessels were present and covered one or more HPFs 1
0
1
2
3
4
0
1
HPFs 2
10
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The following tests were performed on subgroups (n= 3) of
rabbits to assess the extent of phenol-induced pulmonary
toxicity.
2.6.5.1. Lung histologic analysis. Lung damage was assessed
histopathologically after euthanasia by inﬂating and ﬁxing the
left lung with 10% formol saline, embedding the tissue in paraf-
ﬁn and sectioning the tissue for the preparation of microscope
slides. These 5-lm sections were stained with haematoxylin
and eosin. The slides were then evaluated histopathologically
under a light microscope by a pathologist.
2.6.5.2. Assessment of lung oedema. The degree of lung oedema
was evaluated by calculating the lung weight coefﬁcient (LWC)
factor using the following formula (Chen et al., 2004):
LWC= (lung weight/body weight) · 100%. Rabbits were
weighed before being sacriﬁced (body weight). The lungs were
weighed after being removed from the trachea (lung weight).
2.6.5.3. Statistical analysis. A graphical plot was generated to
visualise the variation in blood test results amongst groups
as well as the variation within the groups over time. One-
way repeated measures analysis of variance (ANOVA) was
used to test whether there were any differences between groups
and over time within groups. Statistical signiﬁcance was based
on a p-value <0.05.
3. Results
Histologically, 1% phenol did not cause any lumen narrowing,
but it did cause mild inﬂammation and ﬁbrosis. A concentra-
tion of 5% phenol caused visible fading of the injected ear
veins (Fig. 1). Histologically, 5% phenol caused inﬂammation,
vascular proliferation and ﬁbrosis, which lead to the desired re-
sults and is why it was given 8 points in our scoring system
(Fig. 2). On day 8, it caused up to 90% lumen narrowing
(Fig. 3). 20% phenol caused 100% lumen narrowing, inﬂam-
mation, ﬁbrosis, along with negative undesirable effects like
visible necrosis and loss of ear cartilage and skin (Fig. 4).
50% showed similar results with severe visible necrosis (data
not shown). STS caused approximately 25% lumen narrowingFigure. 1 (A) Rabbit ear before injection (baseline). (B) Rabbit ea
baseline. (C) Rabbit ear one week after injection with 5% phenol, sho
vessel. (D) Rabbit ear 45 days after injection with 5% phenol, showinand was given a score of 5. Normal saline, which was our neg-
ative control, had no effect, as expected. The visible changes
caused by the sclerosant injections are summarised in Table
2. The results of the histologic assessment of the injected blood
vessels are summarised in Table 3.
3.1. Toxicity monitoring
None of the haematologic or biochemical laboratory measure-
ments showed any difference amongst groups. However, there
was a signiﬁcant time effect in AST, ALT, CK-MB and plate-
let counts (Table 4). However, they returned to normal levels
within a week. The graphs in Fig. 5 show the increase or de-
crease of each parameter over time. The lines were parallel
indicating that the interactions were not signiﬁcant, with the
exception of ALT and creatinine.
Histopathologic examination of the hearts revealed that
one animal injected with 50% phenol suffered mild interstitial
oedema and focal pericardial ﬁbrosis. Histopathologic exami-
nation of the lungs showed no signiﬁcant pathology. The cal-
culation of the lung/body weight coefﬁcient indicated that no
oedema was present, as no signiﬁcant differences were
observed between the experimental groups and the controls
(Table 5).
4. Discussion
Our study proposes the use of a new sclerosing agent for the
treatment of VV, a vascular disorder that currently has no per-
manent cure without complications or side effects. VV can
cause heaviness, tiredness, aching discomfort and pain (Bergan
and Pascarella, 2005). Symptoms may be worse after standing
or sitting for long periods of time. Superﬁcial venous insufﬁ-
ciency is a common problem associated with VV, which are
usually asymptomatic but may cause aching, itching, oedema,
or even frank ulceration (Brasic et al., 2008). Disﬁgurement,
disability and impairment in the quality of life of many people
worldwide are also recognised features of VV (Subramonia
and Lees, 2007; Jawien, 2003).
Sclerotherapy has been advocated for the treatment of VV
for over 40 years (Fegan, 1963). Despite this, its value has yet
to be fully established. The sclerotherapy technique consists ofr one hour after injection with 5% phenol, which was similar to
wing mild necrosis and partial disappearance of the injected blood
g nearly complete disappearance of the injected blood vessel.
Figure. 2 (A) Histologic section of a large blood vessel taken
from a rabbit ear 1 h following intravascular 5% phenol injection.
There is marked inﬁltration of the blood vessel wall by numerous
eosinophils (eosinophilic vasculitis), with ﬁbromuscular prolifer-
ation causing partial luminal obstruction (haematoxylin and eosin
stain 200x). (B) High-power view of 2A showing a large number of
inﬁltrating eosinophils in the blood vessel wall. A number of
proliferating ﬁbromyoblasts are also discernible (haematoxylin
and eosin stain 400x).
Figure. 3 (A) Histologic section of a thrombosed blood vessel
taken from a rabbit ear vein at day 8 following intravascular
injection of 5% phenol. Note the presence of a large organised
thrombus obstructing 90% of the blood vessel lumen. The
arrowhead points towards the endothelial lining (haematoxylin
and eosin stain x200). (B) High-power view of 3A showing the
constituents of the obstructing thrombus. The presence of
numerous spindle-shaped ﬁbroblasts (arrowhead) is indicative of
organisation (haematoxylin and eosin stain 400x).
Phenol as a novel sclerosing agent 75injecting a sclerosing agent directly into the VV. The ensuing
inﬂammatory response serves to close off the vein. Many dif-
ferent sclerosing agents have been utilised, but currently, foam
sclerotherapy with a detergent such as STS is favoured by
many clinicians (Worthington-Kirsch, 2005). Sclerotherapy in-
volves the deposit of a foreign substance into a vessel lumen,
which results in thrombosis and ﬁbrosis. Sclerosants cause
endothelial damage, initiating this process. Destruction of
the endothelial layer and resulting exposure of subendothelial
collagen lead to platelet aggregation and activation of the
intrinsic pathway of coagulation (Bergan, 2001). This, in turn,prompts endoﬁbrosis, which ultimately ablates the vein (Sa-
dick, 2005).
Numerous sclerosing agents are used today. However, no
currently available sclerosant possesses all the attributes of
the perfect sclerosing agent. All currently available sclerosants
cause various side effects and permit signiﬁcant recurrence
rates (Duffy, 2010). The strongest and most common scleros-
ing agent currently available is STS (Sadick, 2005).
The results of our present study suggest that phenol is a
promising sclerosing agent for the treatment of VV. High con-
centrations of phenol reaching systemic circulation could be
toxic. Phenol’s side effects include depressed consciousness,
Figure. 4 Visible necrosis of blood vessel and loss of ear
cartilage and skin caused by 20% phenol (day 45).
Table 2 Visible changes that occurred to the injected blood
vessels.
Injection Changes
STSa Partial disappearance of the ear vein and necrosis
Salineb No changes
1% phenol No changes
5% phenol Blood vessel disappeared without necrosis
20% phenol Blood vessel disappeared with necrosis
50% phenol Blood vessel disappeared with necrosis
a Sodium tetradecyl sulphate (positive control).
b Negative control.
Table 4 Tests of group and time effects using ANOVA.
Measurements Groupb,* Timec,* Group and timed,*
AST 0.06 <0.001 0.17
ALT 0.72 <0.001 0.04
BUN 0.83 0.24 0.76
Creatinine 0.25 0.17 0.05
CK-MB 0.49 0.01 0.48
Hb 0.09 0.24 0.41
RBC 0.21 0.21 0.58
WBC 0.57 0.09 0.28
Platelet 0.32 0.02 0.62
* All are p-values.
b Group effect - difference in results between the groups.
c Time effect - difference in the results of repeated measurements
within each group.
d The interactions between groups and time.
76 K.M. AlGhamdi et al.cardiac arrhythmia, acidosis, methaemoglobinaemia, epiglottitis
and laryngeal oedema (O’Neil, 2006). Late complications in-
clude pulmonary oedema, hepatic failure and renal failure
(Hansch et al., 2000; Landau, 2007). The lethal dose of phenol
in rabbits is approximately 600 mg/kg. The half-life is esti-
mated to be between 1 h and 4.5 h, with 52% eliminated un-
changed in the urine (Wexler et al., 1984).
Therefore, small concentrations were chosen in the study to
ﬁnd the minimal effective concentration of phenol that would
give optimum results and reduce the incidence and severity of
adverse sequelae. The concentration of 1% phenol was too low
to cause lumen narrowing, although it caused inﬂammation
and ﬁbrosis. The concentration of 5% phenol caused partial
lumen narrowing within 1 h of injection and reached almostTable 3 Results of the histologic assessment of the injected blood
Animal Inﬂammation Vascular proliferation Lumen narrowin
STSa 1+ 1+ 1+ (25%)
Salineb 1+ 0 0
1% phenol 2+ 0 0
5% phenol 2+ 1+ 4+ (90%)
20% phenol 2+ 0 4+ (100%)
50% phenol 0 0 4+ (100%)
a Sodium tetradecyl sulphate (positive control).
b Negative control.
c The mean of the data for each group is shown.
d Refer to Table 1 for details of the scoring system.complete lumen narrowing by day 8 that lasted for 45 days,
with no side effects such as haemorrhage or necrosis, while
STS only caused 25% lumen narrowing. Concentrations of
20 and 50% phenol caused 100% lumen narrowing but also
caused negative effects including haemorrhage and severe
necrosis. These results indicate that 5% phenol may be the
optimum concentration for use as a sclerosing agent to treat
varicose veins, as it gave much better results than the current
predominant treatment, STS.
Toxicity monitoring showed no apparent haematologic,
cardiac, pulmonary, hepatic or renal toxicities associated with
the concentrations of phenol used in the study. There were no
signiﬁcant differences amongst the phenol, STS, and saline
groups for any toxicity parameter. The lack of signiﬁcant dif-
ferences means that phenol as used in our study is not causing
toxicity. The slight elevation in some of the results returned to
normal within a week. This indicates that phenol, which gave
better sclerosing effects, is not more toxic than STS.
Some of the most common side effects associated with STS
include residual pigmentation and thrombophlebitis (Kanter,
1995). Other side effects include necrosis and ulceration, which
are caused by leakage outside the vein or from using a concen-
tration that is too high (Sadick, 2005). Allergic reactions are
rare and present as local or generalised rash, urticaria, nausea
or vomiting, asthma and vascular collapse. Anaphylactic
shock, which may potentially be fatal, is extremely rare but re-
mains a possibility (Blenkinsopp, 1968; Kanter, 1995). The
small phenol concentration suggested (5%) did not cause anyvesselsc,d.
g Fibrosis Additional features Total score
2+ Extravascular haemorrhage 5+
0 None 1+
1+ Oedema 3+
1+ Eosinophilic inﬁltration 8+
1+ Haemorrhage 7+
0 Haemorrhag and necrosis in vessel wall 4+
Figure. 5 Graphical plots showing the differences in the means of the haematologic and biochemical laboratory results (y-axis) between
groups* as well as within groups** (repeated measurements over a period of time, x-axis). *Group 1 – Sodium tetradecyl sulphate (positive
control). Group 2 – Normal saline (negative control). Group 3 – 1% Phenol. Group 4 – 5% Phenol. Group 5 – 20% Phenol. Group 6 –
50% Phenol. **Repeated measurements at 1 h, day 1 and day 8 after injection, corresponding to 1, 2 and 3, respectively.
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Table 5 Lung/body coefﬁcient (mean ± SD) of rabbit lungs
in each group.
Group Lung/body weight coeﬃcient (%)
STSa 0.546 ± 0.012
Salineb 0.533 ± 0.012
1% phenol 0.567 ± 0.035
5% phenol 0.516 ± 0.079
20% phenol 0.489 ± 0.034
50% phenol 0.502 ± 0.025
a Sodium tetradecyl sulphate (positive control).
b Negative control.
78 K.M. AlGhamdi et al.of the mentioned side effects, which implies that phenol could
be a much better therapeutic option.
Our results show that 5% phenol is a promising sclerosing
agent that is cheap, readily available and easy to prepare for
the treatment of varicose veins, with minimal side effects.
The limitation of our study is the small sample size, which pre-
cludes making a solid statistical conclusion. The strength of
our study lies in the demonstration of a potential new scleros-
ing agent, as well as testing different concentrations to suggest
the concentration that gives optimum results with minimal side
effects. However, further studies with a larger sample size are
needed to further test phenol as a sclerosing agent before
applying it to treat human VV. Also, other formulations of
phenol could be tested for better results.
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